International
The Morning Science

What science found today

‹
 

Research

Tirzepatide Cuts BMI in Adolescents With Obesity in Phase III Trial

MedPage Today ·

Tirzepatide Cuts BMI in Adolescents With Obesity in Phase III Trial

The Brief

  • Tirzepatide (Zepbound) produced substantial reductions in BMI among adolescents with obesity or overweight with obesity-related complications.
  • The results come from the phase III SURMOUNT-ADOLESCENTS trial.
  • The findings were reported at ObesityWeek in National Harbor, Md.

Why it matters

The phase III trial provides evidence on BMI outcomes of tirzepatide in adolescents, a population with fewer treatment studies than adults.

Who’s affected

  • clinicians treating adolescents with obesity
  • adolescents with obesity and their families

(MedPage Today) -- NATIONAL HARBOR, Md. -- Tirzepatide (Zepbound) yielded substantial reductions in BMI among adolescents with obesity or overweight with obesity-related complications, the phase III SURMOUNT-ADOLESCENTS trial showed. At week...

Timeline

  1. MedPageToday.com - medical news for physicians

    Tirzepatide Cuts BMI in Adolescents With Obesity in Phase III Trial

  2. Phase III SURMOUNT-ADOLESCENTS results presented at ObesityWeek

How do you feel about this?

0 Comments

    Tirzepatide Cuts BMI in Adolescents With Obesity in Phase III Trial – The Morning Science